481 related articles for article (PubMed ID: 25746091)
1. Polymeric drug delivery for the treatment of glioblastoma.
Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
4. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
5. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
6. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
[TBL] [Abstract][Full Text] [Related]
7. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Xing WK; Shao C; Qi ZY; Yang C; Wang Z
Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results.
Salmaggi A; Milanesi I; Silvani A; Gaviani P; Marchetti M; Fariselli L; Solero CL; Maccagnano C; Casali C; Guzzetti S; Pollo B; Ciusani E; Dimeco F
J Neurosurg; 2013 Apr; 118(4):821-9. PubMed ID: 23350777
[TBL] [Abstract][Full Text] [Related]
9. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
[TBL] [Abstract][Full Text] [Related]
11. Outcome of patients affected by newly diagnosed glioblastoma undergoing surgery assisted by 5-aminolevulinic acid guided resection followed by BCNU wafers implantation: a 3-year follow-up.
Della Puppa A; Lombardi G; Rossetto M; Rustemi O; Berti F; Cecchin D; Gardiman MP; Rolma G; Persano L; Zagonel V; Scienza R
J Neurooncol; 2017 Jan; 131(2):331-340. PubMed ID: 27757721
[TBL] [Abstract][Full Text] [Related]
12. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma.
Samis Zella MA; Wallocha M; Slotty PJ; Isik G; Hänggi D; Schroeteler J; Ewelt C; Steiger HJ; Sabel M
Acta Neurochir (Wien); 2014 Feb; 156(2):313-23. PubMed ID: 24287680
[TBL] [Abstract][Full Text] [Related]
14. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Sabel M; Giese A
Curr Med Res Opin; 2008 Nov; 24(11):3239-57. PubMed ID: 18940042
[TBL] [Abstract][Full Text] [Related]
15. Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Balossier A; Dörner L; Emery E; Heese O; Mehdorn HM; Menei P; Singh J
Clin Drug Investig; 2010; 30(3):195-204. PubMed ID: 20155992
[TBL] [Abstract][Full Text] [Related]
16. Carmustine wafer implantation when surgical cavity is communicating with cerebral ventricles: technical considerations on a clinical series.
Della Puppa A; Rossetto M; Ciccarino P; Denaro L; Rotilio A; d'Avella D; Scienza R
World Neurosurg; 2011; 76(1-2):156-9; discussion 67-8. PubMed ID: 21839967
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Pan E; Mitchell SB; Tsai JS
J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
[TBL] [Abstract][Full Text] [Related]
18. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Lin SH; Kleinberg LR
Expert Rev Anticancer Ther; 2008 Mar; 8(3):343-59. PubMed ID: 18366283
[TBL] [Abstract][Full Text] [Related]
19. Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Kleinberg LR; Weingart J; Burger P; Carson K; Grossman SA; Li K; Olivi A; Wharam MD; Brem H
Cancer Invest; 2004; 22(1):1-9. PubMed ID: 15069758
[TBL] [Abstract][Full Text] [Related]
20. The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Engelhard HH
Surg Neurol; 2000 May; 53(5):458-64. PubMed ID: 10874145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
